- Home
- SGN vs SBFM Comparison
SGN vs SBFM Comparison
Compare SGN & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- SBFM
- Stock Information
- Founded
- SGN 2019
- SBFM 2006
- Country
- SGN United States
- SBFM United States
- Employees
- SGN N/A
- SBFM N/A
- Industry
- SGN
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- SGN
- SBFM Health Care
- Exchange
- SGN Nasdaq
- SBFM Nasdaq
- Market Cap
- SGN 7.8M
- SBFM 6.7M
- IPO Year
- SGN 2023
- SBFM N/A
- Fundamental
- Price
- SGN $1.48
- SBFM $1.77
- Analyst Decision
- SGN
- SBFM Strong Buy
- Analyst Count
- SGN 0
- SBFM 1
- Target Price
- SGN N/A
- SBFM $7.00
- AVG Volume (30 Days)
- SGN 220.9K
- SBFM 2.2M
- Earning Date
- SGN 11-12-2025
- SBFM 11-12-2025
- Dividend Yield
- SGN N/A
- SBFM N/A
- EPS Growth
- SGN N/A
- SBFM N/A
- EPS
- SGN N/A
- SBFM N/A
- Revenue
- SGN $391,126.00
- SBFM $36,341,741.00
- Revenue This Year
- SGN N/A
- SBFM $21.12
- Revenue Next Year
- SGN N/A
- SBFM $44.89
- P/E Ratio
- SGN N/A
- SBFM N/A
- Revenue Growth
- SGN N/A
- SBFM 19.22
- 52 Week Low
- SGN $0.44
- SBFM $1.17
- 52 Week High
- SGN $13.72
- SBFM $3.90
- Technical
- Relative Strength Index (RSI)
- SGN 41.28
- SBFM 50.94
- Support Level
- SGN $1.38
- SBFM $1.81
- Resistance Level
- SGN $1.66
- SBFM $2.13
- Average True Range (ATR)
- SGN 0.12
- SBFM 0.17
- MACD
- SGN -0.02
- SBFM -0.03
- Stochastic Oscillator
- SGN 20.08
- SBFM 24.14
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.